ALK and non-small cell lung carcinoma: In phase I trials, crizotinib, the first-generation ALK-TKI, achieved an objective response rate (ORR) of 57% in ALK-positive advanced NSCLC, leading to its approval as the first ALK inhibitor for clinical use (9).